Physician
The Center for Pain of Montgomery LLC
The Center for Pain of Montgomery LLC was paid $5.88M by Medicaid between Jan 2018 and Dec 2024, across 34 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 39% of everything it billed.
33Billing provider infoTHE CENTER FOR PAIN OF MONTGOMERY LLC
MONTGOMERY, AL 36116
MONTGOMERY, AL 36116
33aNPI1588710289assigned 01/26/2007
33bProvider typeInterventional Pain Medicine Physician
28Total paid$5.88M
24GClaims198,784
24DCodes billed34
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Interventional Pain Medicine Physician providers in Alabama
Rank by total paid#1 of 9
Median peer was paid$29K
This provider vs. median206×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 15,849 | $374K | |
| 2019 | 18,351 | $502K | |
| 2020 | 22,840 | $612K | |
| 2021 | 37,318 | $754K | |
| 2022 | 30,454 | $866K | |
| 2023 | 42,437 | $1.51M | |
| 2024incomplete | 31,535 | $1.26M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 39% | 68,768 | 52,851 | $2.31M |
| 62323 | 16% | 11,066 | 8,260 | $937K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 6.1% | 11,272 | 7,965 | $356K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.8% | 19,096 | 15,594 | $340K |
| 62321 | 5.6% | 3,640 | 2,645 | $329K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 5.2% | 3,742 | 2,812 | $305K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 4.1% | 3,602 | 2,803 | $239K |
| 64483 | 3.6% | 1,707 | 977 | $213K | |
| 64635 | 2.5% | 1,197 | 634 | $147K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 2.3% | 2,354 | 1,720 | $138K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 2.3% | 22,000 | 16,051 | $133K |
| 64636 | 1.6% | 1,582 | 622 | $95K |
22 more codes
| 27096 | 1.2% | 824 | $70K | |
| 64493 | <1% | 1,064 | $55K | |
| 20610 | <1% | 2,388 | $54K | |
| 77002 | <1% | 2,193 | $48K | |
| 64494 | <1% | 1,069 | $30K | |
| 64495 | <1% | 425 | $16K | |
| 99205 | Prolong outpt/office vis | <1% | 155 | $15K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 252 | $11K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,838 | $9K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,350 | $8K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 41 | $6K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 25,494 | $6K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 59 | $3K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 88 | $2K |
| 64484 | <1% | 38 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 566 | $2K |
| J7328 | Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg | <1% | 18 | $2K |
| 99442 | <1% | 610 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,431 | $1K |
| 0001A | <1% | 20 | $186.34 | |
| 91300 | 0% | 43 | $0.00 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 792 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKATZ, BRADLEY (OWNER/PHYSICIAN)